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patent applications, and regulatory quality have been controlled for. Negative impacts 
of the recent reforms on R&D expenditures for Germany and Norway and, in some 
instances, for Italy and Japan are detected. A positive impact of the 2003 reform on 
R&D related indicators has been found for the US. The reforms reduced R&D expen-
ditures by 0.76% for Italian ﬁrms, decreased R&D intensity of Norwegian ﬁrms by 
2.42%, lowered cash ﬂows of French ﬁrms by 0.72%, but increased the R&D of 
American ﬁrms by 0.27%. These results can be explained by the degree of the reform 
rigidness for price and reimbursement controls, drug development lags, the importance 
of R&D for competition and ﬁrm valuation, and growing exports to less regulated 
markets. The results can also be explained with a theoretical R&D reproduction cycle 
model. CONCLUSIONS: Stronger shifts to more rigid cost-containment reimburse-
ments impeded R&D expenditures. However, despite the adverse regulatory shocks, 
most ﬁrms’ R&D related indicators tend to be persistent in the short run.
DE4
PRESCRIPTION DRUG FORMULARIES AND COVERAGE: DOES A DRUG 
BY ANY OTHER NAME SMELL AS SWEET?
Hsu J, Price M, Fung V
Kaiser Permanente, Oakland, CA, USA
OBJECTIVES: We investigated the impact of eliminating brand name drug coverage 
on statin drug spending, adherence, and physiologic outcomes in a cohort of Medicare 
beneﬁciaries, compared with a concurrent control group of beneﬁciaries with coverage 
of both brand and generic drugs. METHODS: All subjects were age 65 years. In 
2002–03, beneﬁciaries with restricted coverage had an annual drug beneﬁt cap of 
$1,000; in 2004–05, these beneﬁciaries lost brand name drug coverage, but had no 
coverage limits for generics. Controls had no restrictions or changes in brand/generic 
coverage 2002–05. We used ﬁxed-effects regression models to examine the association 
between coverage and quarterly outcomes. We adjusted for time-varying covariates 
including time, comorbidity (DxCG scores), plus time*coverage interactions. 
RESULTS: The 66,051 subjects had a mean age of 73.6 years, and 50% were female. 
In 2002, 53% of subjects had restricted beneﬁts, and the remaining had no drug beneﬁt 
restrictions. Compared to those with unrestricted beneﬁts and after multivariate adjust-
ment, subjects with restricted beneﬁts had less spending on and worse adherence to 
statin drugs, and worse LDL levels, particularly after the elimination of brand drug 
coverage: for example, statin drug spending differences were $35/quarter (95%CI: 
$32–37); the odds ratio of non-adherence was 1.27 (95% CI:1.19–1.36); and LDL 
differences were 2.00 mg/dL (95% CI:1.65–2.34 mg/dL) for subjects with restricted 
vs. unrestricted coverage, in Q4 2004 vs. Q1 2002. The LDL differences were related 
primarily to reductions in the prescribed daily dose among those with restricted cover-
age; in 2003, 10% of subjects had prescriptions above the maximum recommended 
dose of lovastatin, the only available generic during the study period. CONCLUSIONS: 
Prescription drugs within a therapeutic class are not all clinically equivalent, even 
within narrow classes with few differences such as statins. Careful attention is needed 
to the clinical needs of individual patients when imposing drug coverage restrictions.
PODIUM SESSION I: MENTAL HEALTH – MODELING STUDIES
MH1
A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE 
DISORDER—COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE
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OBJECTIVES: Most published cost-effectiveness analyses related to depression have 
used Markov models. However, evidence shows that probabilities of relapse and 
remission of depressive episodes are time and past events dependent, suggesting the 
appropriateness of discrete event simulation models (DESM). Our aim was to assess 
the cost-effectiveness of agomelatine in major depression from the Portuguese societal 
perspective using a DESM. METHODS: Sequential time to remission and time to 
relapse/recurrence were sampled from weibull distributions. Remission rates were 
obtained from a meta-analysis of randomized, venlafaxine-controlled clinical trials 
with either agomelatine, escitalopram, ﬂuoxetine, paroxetine or sertraline. Probability 
of relapse/recurrence was assumed dependent on the number of previous depressive 
episodes and time since last remission. We compared agomelatine 25 mg/day with 
possible dose titration to a mixed comparator composed by escitalopram(12 mg/- 
day), ﬂuoxetine(38 mg/day), paroxetine(25 mg/day), sertraline(116 mg/day) and 
venlafaxine(150 mg/day), weighted according to the deﬁned daily doses consumed 
between January and June 2008. Only direct costs were considered (drugs, medical 
visits, side effects treatments and monitoring). Effectiveness was measured in quality-
adjusted life years (QALY) and life years in remission (LYR). Time horizon varied 
from 6 to 37 months according to each individual simulation characteristics. When 
appropriate discount rates of 5%/year were applied to costs and effectiveness. 
RESULTS: A gain of 9.4 QALY (95%CI:[6.2;12.4]) or 10 LYR (95%CI:[5.2;15]) was 
estimated for each 100 patients treated with agomelatine. The estimated incremental 
cost of agomelatine treated patients was a325 (95%CI:[167; 827]). Corresponding 
incremental cost-effectiveness ratios were a3460/QALY or a3197/LYR. Probabilistic 
sensitivity analysis revealed 11% probability of agomelatine dominance and 97.5% 
of being cost-effective at a threshold of a10,000, regardless of the effectiveness measure 
considered. CONCLUSIONS: DESM is a valuable tool to model the cost-effectiveness 
of major depression. Agomelatine is a cost-effective drug for the treatment of major 
depressive disorder in Portugal, when compared to current clinical practice.
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Van den Berg M1, Smit F2, Vos T3, Van Baal P4
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OBJECTIVES: Depression causes a large burden of disease worldwide. Effective pre-
vention has the potential to reduce that burden considerably. We investigated the 
cost-effectiveness of minimal contact psychotherapy, based on Lewinson’s ‘Coping 
with depression’ course, targeted at opportunistically screened individuals with sub-
threshold (minor) depression. METHODS: We compared the costs and effects of an 
intervention scenario (all persons in the target population are screened and those with 
sub-threshold depression receive preventive minimal contact psychotherapy) with a 
current practice scenario. Using a Markov model, future health effects and costs were 
estimated from both the health care and the societal perspective. Incremental cost 
effectiveness ratios (ICER) were expressed in euro per DALY averted. Costs were dis-
counted at 4% and effects at 1.5%. The time horizon was ﬁve years. Probabilistic 
sensitivity analysis was employed to study the effect of uncertainty in the model 
parameters. RESULTS: From the health care perspective the incremental cost-
 effectiveness ratio was a4000 per DALY, and from the societal perspective the inter-
vention was even cost saving. CONCLUSIONS: This modeling study showed that 
from a health care perspective health gains can be achieved at a low cost if opportu-
nistic screening for sub-threshold depression in combination with MCP is implemented 
in a primary care setting. From a societal perspective, the modeled strategy of depres-
sion prevention is even cost saving.
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ANTIPSYCHOTIC USE AND DIABETES: A NESTED CASE-CONTROL 
ANALYSIS IN A COHORT OF NEW ANTIPSYCHOTIC USERS
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The association between the use of some antipsychotic drugs and diabetes mellitus is 
still controversial. OBJECTIVES: To assess the risk of diabetes mellitus in new users 
of antipsychotic drugs. METHODS: A nested case-control study using the Quebec 
Health Insurance Board databases. The source cohort was made of diabetes-free 
people who initiated antipsychotic treatment between January 1, 2000 and march 31, 
2007. Cases were cohort members who initiated antidiabetic treatment or had a 
diagnosis of diabetes during their follow-up period. Ten matched (for sex, age, year 
of treatment initiation) controls were selected using density sampling method. A 6-
value variable was used to assess exposure to antipsychotic: any typical, clozapine, 
olanzapine, quetiapine, risperidone or more than one drug. A paired multivariate 
logistic regression model was used to calculate adjusted odds ratios (OR). Co-variates 
included current user status, number of days of exposure to antipsychotic treatment, 
patient characteristics, use of other drugs and of health services. RESULTS: Among 
the 67,515 individuals included in the cohort, 1,715 cases of diabetes were identiﬁed 
and were matched to 17,143 controls. No difference was observed across atypical 
antipsychotic users. Longer exposure to any antipsychotic treatment was associated 
with diabetes [OR for each 30-day period: 1.05 (CI: 1.03–1.07)]. Individuals living in 
an urban area, those with low SES, those in the two highest tertiles of the number of 
different drugs used and of the number of medical visits, those who had been hospital-
ized, and those exposed q80% of the time period to drugs others than antipsychotic 
that can increase the risk of diabetes were more likely to develop the disease [OR: 
1.23 (CI: 1.03–1.46)]. CONCLUSIONS: Duration of exposure to antipsychotic treat-
ment is associated with diabetes, regardless of atypical antipsychotic agent. One limita-
tion to this analysis is that aripiprazole and ziprasidone were not available and thus 
no conclusion can be drawn.
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COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 
DIABETES MELLITUS (T2DM): EFFECTS ON QUALITY OF LIFE AND 
RESOURCE USE
Purayidathil FW, Gupta S, Wagner S
Consumer Health Sciences International (a KantarHealth Company), Princeton, NJ, USA
OBJECTIVES: To evaluate the impact of T2DM with comorbid depression on Patient 
Reported Outcomes (PROs) and health care resource use in France, Germany Italy, 
Spain and the UK. METHODS: Data were from respondents self-reporting diagnosis 
of T2DM in the 2008 U.S. National Health and Wellness Survey (NHWS), an annual 
cross-sectional survey of health care attitudes, behaviors, disease states, and outcomes 
of adults aged 18. Depression symptoms were deﬁned by afﬁrmative responses in the 
past month to: bothered by feeling down, depressed or hopeless and bothered by 
having little interest or pleasure in doing things. Outcomes included health care utiliza-
tion in the past six months and SF-12v2 summary scores. Regression models assessed 
independent effects of depression on outcomes and resource use, adjusting for gender, 
age, country, marital status, education, and an adjusted Charlson Comorbidity Index 
score. RESULTS: Among 2,668 respondents diagnosed with T2DM, 828 (31%) were 
female and 750 (28%) experienced symptoms of depression. After controlling for 
covariates, patients with comorbid depression had lower SF-12v2 physical and mental 
summary scores of 5.3 (p  0.0001) and 15.7 (p  0.0001), respectively; however, 
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patients with T2DM in the UK had signiﬁcantly lower (p  0.0001) physical summary 
scores than other EU countries. Patients experiencing depression symptoms were more 
likely to visit the ER [OR  1.74; 95% CI:(1.35, 2.23); p  0.0001], be hospitalized 
[OR  1.43; 95% CI:(1.11, 1.84); p  0.005] and had more physician visits in the last 
six months (B  5.37, p  0.0001). Patients in Spain had signiﬁcantly more provider 
visits (p  0.05) and ER visits (p  0.0001) than UK patients, while patients in France 
were hospitalized more often than UK patients (p  0.05). CONCLUSIONS: Comor-
bid depression in patients with T2DM greatly decreases physical and mental summary 
scores of the SF-12, and increases resource use. Further research is needed to clarify 
associations between the two conditions, including geographical and cultural inﬂu-
ences on health outcomes in this cohort.
PODIUM SESSION I: UTILITY MEASUREMENTS STUDIES
UT1
VALUING EQ-5D USING TIME TRADE-OFF IN FRANCE
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OBJECTIVES: The EQ-5D questionnaire has been developed and validated in France 
but the utility function has not been elicited. The main objective of the present study 
is to provide a French value-set for the EQ-5D health states using the Time Trade-Off 
(TTO) method. METHODS: A total of 452 respondents aged over 18 were recruited 
for a French valuation study. They were chose to be representative of the French 
population with regard to age, gender and socio-professional group. Twenty four 
EQ-5D health states were selected to be directly valued. Three groups of 300 respon-
dents were set up and each group valued 17 of 24 EQ-5D health states using the time 
trade-off (TTO) method. The TTO valuations were linearly transformed to lie on the 
interval [1;1]. Exclusion criteria used were the same as in other valuation studies. 
We also investigated logical inconsistencies. Several alternative models speciﬁcations 
were investigated to estimate the values of the remaining non direct valuated EuroQol 
health states. The analysis was conducted at an individual level to make the maximum 
use of the available data and we estimated mixed models with random intercept. 
Models were compared using different goodness of ﬁt measures: the Akaike’s informa-
tion criterion (AIC), the Mean Absolute Error (MAE) and the Pearson correlation 
between the observed and the predicted value. RESULTS: After exclusion, 443 respon-
dents take part in the study. Fifty three respondents (12%) present more than 10 
logical inconsistencies in their responses. The model presenting the smaller Akaike’s 
information criterion include the same variables as the N3-model used in UK. This 
model yield a good ﬁt for the TTO data with a mean absolute error of 0.04 and a 
Pearson correlation coefﬁcient of 0.99. CONCLUSIONS: This study will provide the 
ﬁrst EQ-5D value set for France.
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PARADIGM LOST: A CONCEPTUAL AND EMPIRICAL OBITUARY 
CHRONICLING THE DEMISE OF CARDINAL UTILITY MEASUREMENTNT
Kind P
University of York, York, UK
OBJECTIVES: The choice of quality-adjustment factor, as stipulated by health eco-
nomics and as required by regulatory agencies, dictates that the “Q” in QALY should 
be a utility (choice-based preference) measure. This requirement has led to a state of 
chaos in which multiple utility elicitation methods are permitted and in which no test 
of their relative performance has been documented. This paper reﬂects the current 
status of utility measurement as applied in QALY calculations and conclusively dem-
onstrates its fallibility. METHODS: The paper is divided into two parts, the ﬁrst of 
which rehearses the basic measurement requirements for any viable metric used as a 
quality-adjustment scalar and deals with the impossibility of permitting mutually 
incompatible utility elicitation procedures. It concludes with a novel test of uniqueness 
that can be applied to competing sets of utility weights. The second part is based on 
empirical evidence generated in the MVH study in which both TTO and VAS ratings 
were used to calibrate EQ-5D for use in economic evaluation conducted in the UK 
(n  3395). Analysis compares the within-respondent ordinal preferences captured 
through VAS rating with those inferred by TTO utilities. RESULTS: Nearly 50% of 
respondents had a Spearmans rho below 0.8, corresponding to a mean difference in 
rank of around 4 between VAS and TTO scores. Twenty-six percent of respondents 
assigned a utility of 1.0 (full health) to 3 or more health states with differing degrees 
of dysfunction. More than 40% of respondents fail to distinguish between full health 
and the 5 mildest health states. CONCLUSIONS: The demonstrable frailty of utility 
elicitation methods is well-known. Research scientists in general and health economists 
in particular should be wary of encouraging others to accept QALY metrics of this 
type. The continued requirement for utility measures in social decision-making com-
promises both the science and the scientists who tolerate its misuse.
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HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE 
ROTAVIRUS INFECTIONS
Hauber AB1, Johnson FR1, Cook JR2, Mohamed AF1, Gonzalez JM1, Walter E3
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Conventional standard-gamble and time-tradeoff methods may be inappropriate for 
eliciting preferences for acute, nonfatal health states because both require subjects to 
evaluate tradeoffs between a morbid health state and death. OBJECTIVES: This study 
demonstrates the use of conjoint analysis with a discrete-choice experimental design 
to obtain estimates of healthy-days equivalents (HDEs) for clinically relevant durations 
and severities for rotavirus gastroenteritis, an acute diarrheal illness common in young 
children. METHODS: Parents of children a5 years of age completed a web-enabled 
survey instrument that presented a series of trade-off questions to elicit judgments 
about the relative seriousness of pairs of hypothetical gastrointestinal illnesses. Each 
illness was deﬁned by seven attributes: diarrhea, vomiting, fever, seizure, behavioral 
changes, dehydration, and illness duration. A random-parameters ordered-probit 
model was developed to estimate the preference weights for each symptom-severity 
level. RESULTS: A total of 229 parents completed the survey. Subjects judged seizure 
to be the worst rotavirus symptom, followed by dehydration, vomiting, fever, and 
diarrhea. Parents rated behavioral changes as the least bothersome symptom of rota-
virus. Estimated preference weights indicate improvements in each symptom relative 
to its worst level. As the duration of the illness increases, so does the decrement in 
HDEs. The decreases in time equivalents for 3-day and 7-day illnesses with seizure 
are 0.7 and 2.3 HDEs, respectively, while the corresponding decreases for illnesses 
with diarrhea are 0.3 and 1.0 HDE, respectively. These results imply that seizure is 
subjectively about 2.3 times more important than nine loose bowel movements per 
day. CONCLUSIONS: Results indicate that the trade-off data support valid estimates 
of HDEs for acute conditions ranging in duration from one day to two weeks without 
requiring subjects to make implausible comparisons between acute, self-limiting condi-
tions and mortality risks or longevity reductions.The results can be used for cost-
effectiveness analysis in place of conventional time-equivalents.
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OBJECTIVES: To select and test severity labels for a new, ﬁve-level version of the 
EQ-5D. METHODS: The EQ-5D is a generic instrument for describing and valuing 
health. Each dimension (Mobility, Self-Care, Usual activities, Pain/discomfort, 
Anxiety/depression) is currently measured on 3 levels of health (no problems, some 
problems, extreme problems). A EuroQol Group task force was established to ﬁnd 
ways of improving the instrument’s sensitivity to small and medium changes in health 
and reducing the ceiling effect. The study used a two-stage approach: i) response 
scaling was performed in the UK and Spain to explore the severity represented by 
potential new labels that could be used as additional or replacement levels within each 
dimension. Labels as close as possible to the 25th, 50th and 75th centiles were selected 
for further testing; ii) the face and content validity of alternative 5-level versions were 
investigated in 8 focus groups of healthy participants and patients in each country. 
Hypothetical health states based on a revised labeling system were also reviewed. 
RESULTS: Rank ordering of severity labels was similar across dimensions and coun-
tries. Selecting labels at approximately the 25th, 50th and 75th centiles produced two 
alternative 5-level versions. Focus group work showed a slight preference for the 
wording ‘slight-moderate-severe’ problems, with anchors of ‘no problems’ and ‘unable 
to do’ in the EQ-5D functional dimensions. Similar wording was used in the Pain/dis-
comfort and Anxiety/depression dimensions. Focus group comments indicated that, 
although not always colloquial, the magnitude of problems represented by the new 
labels was well understood. Comments on hypothetical health states referred more 
to their internal consistency than to the labels, which were again well understood. 
CONCLUSIONS: This study represents the ﬁrst step towards developing an ofﬁcial 
5-level version of the EQ-5D. Testing in patient settings and development of the cor-
responding health state valuations is required.
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COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU)  
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The concept of QALYs has been introduced to compare therapies in widely separated 
areas of medicine. Many of the more recent developments in oncology are considered 
too costly in terms of prices for an additional QALY gained. Here we try to apply 
the concept to PCU-care in Germany, an area, with a high proportion of oncology 
